Moderna stock hits 52-week low at $33.31 amid market challenges

Published 01/13/2025, 09:31 AM
©  Reuters
MRNA
-

In a turbulent market environment, Moderna Inc . (BMV:MRNA) stock has tumbled to a 52-week low, touching down at $33.31. With a market capitalization of $16.26 billion, the company maintains a healthy liquidity position, reflected in its current ratio of 4.39. The biotechnology company, known for its pivotal role in developing a COVID-19 vaccine, has faced a challenging year, with its stock price reflecting a significant downturn. Over the past year, Moderna (NASDAQ:MRNA)'s shares have witnessed a precipitous decline, with the 1-year change data showing a staggering drop of -60.12%. According to InvestingPro analysis, analyst price targets range from $31 to $212, reflecting divided opinions on the company's prospects. This sharp decrease underscores the volatility and uncertainty that have gripped the biotech sector, as investors reassess the post-pandemic landscape and Moderna's future revenue streams, with analysts anticipating a significant sales decline in the current year.

In other recent news, Moderna has revised its 2025 revenue forecast downwards, now anticipating sales to fall between $1.5 billion and $2.5 billion, a significant decrease from the previous consensus forecast of $2.92 billion. This has prompted the company to increase its cost-cutting measures in an effort to maintain a cash reserve of approximately $6 billion by 2025. Amidst these financial developments, Bernstein SocGen Group has maintained a Market Perform rating for Moderna, pointing out that the company's current product offerings do not directly benefit from the increased attention on respiratory diseases.

Recent events have seen Moderna's shares surge due to growing concerns over the bird flu and an increase in influenza, COVID, and Respiratory Syncytial Virus (RSV) cases. Despite this, Bernstein SocGen Group suggests that Moderna's financial performance may not be significantly impacted by these respiratory infections. They note that Moderna's MResvia, a vaccine for RSV, holds a minor position in the market and that high infection rates could potentially reduce the number of vaccinations.

In other company news, Moderna has recently received $176 million in funding from the U.S. Department of Health to advance a vaccine for H5N1 bird flu. These are recent developments for Moderna in the face of rising flu cases and increased demand for vaccines.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.